A program of immune-based treatments for cancer

描述（由申请人提供）：本提案的目标是将卡森博士实验室的免疫学发现转化为癌症患者的临床试验，并将本研究计划用作培训年轻医生进行以患者为导向的研究的手段。一些最令人兴奋的新抗癌疗法是基于免疫学的发现。重组细胞因子和单克隆抗体现在常规用于治疗癌症患者。卡森博士的临床计划集中在两个具体的调查领域：1）。免疫刺激化合物用于增强对治疗性抗肿瘤单克隆抗体的免疫应答的用途，和2）。细胞因子单独或与靶向药物联合治疗转移性黑素瘤患者的用途。这里介绍的大多数试验都是从卡森博士免疫学实验室的基本实验观察发展而来的。卡森博士的试验是独一无二的，因为它们结合了一系列深入的相关研究，旨在评估治疗方案对患者免疫系统活性和患者肿瘤生长的影响。这些实验室研究允许对免疫方案进行合理评价，并指导了后续试验的开展。此外，他们还允许卡森博士从国家癌症研究所和其他校外来源为他的临床研究吸引资金。结合这些临床活动，卡森博士为年轻的研究人员制定了一个以患者为导向的研究系统培训计划。俄亥俄州州立大学综合癌症中心的一些内科和外科肿瘤学研究员、外科住院医生和早期职业助理教授参与了卡森博士临床试验的开发和实施。该计划的目标是教参与者如何通过直接的患者互动和专业的辅导课程来生成和管理自己设计的协议。学员还将参加一系列肿瘤学教学会议，并定期与卡森博士会面，讨论他们的病人和他们的教育经验。卡森医生作为国家私家侦探的角色。在一个随机试验的化疗与或不抗血管生成药物（贝伐单抗，阿瓦斯丁（商标））确保学员也将获得宝贵的经验，在这方面的临床研究。最后，一个特别的重点放在了有关的指导以病人为导向的研究的道德行为。

DESCRIPTION (provided by applicant): The goals of this proposal are to translate immunologic discoveries from Dr. Carson's laboratory into clinical trials for cancer patients and to use this research program as a means of training young physicians in patient-oriented research. Some of the most exciting new anti-cancer therapies are based on immunologic discoveries. Recombinant cytokines and monoclonal antibodies are now routinely used to treat cancer patients. Dr. Carson's clinical program has focused on two specific areas of investigation: 1). The use of immunostimulatory compounds to augment the immune response to therapeutic anti-tumor monoclonal antibodies, and 2). The use of cytokines alone or in combination with targeted agents to treat patients with metastatic melanoma. The majority of the trials presented here have evolved from basic experimental observations that were made in Dr. Carson's immunology laboratory. Dr. Carson's trials are unique in that they incorporate a series of in-depth correlative studies designed to evaluate the effects of the treatment regimen on the activity of the patient's immune system and the growth of the patient's tumor. These laboratory studies have permitted a rational evaluation of the immunotherapeutic regimens and have guided the development of subsequent trials. In addition, they have allowed Dr. Carson to attract funding for his clinical research from the NCI and other extramural sources. In conjunction with these clinical activities, Dr. Carson has developed a systematic training program in patient-oriented research for young investigators. A number of Medical and Surgical Oncology Fellows, surgical residents, and early career Assistant Professors at the Ohio State University Comprehensive Cancer Center have participated in the development and conduct of Dr. Carson's clinical trials. The goal of this program is to teach participants how to generate and administer protocols of their own design via direct patient interaction and specialized tutorial sessions. Trainees will also attend a series of oncologic didactic sessions and meet regularly with Dr. Carson to discuss their patients and their educational experiences. Dr. Carson's role as national P.I. on a randomized trial of chemotherapy with or without an anti-angiogenic drug (bevacizumab, Avastin(tm)) insures that trainees will also gain valuable experience in this aspect of clinical research. Finally, a special emphasis has been placed on instruction relating to the ethical conduct of patient-oriented research.